Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
November 27, 2024 7:14 AM ESTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR).
The analyst comments "Arrowhead has announced a new global licensing and collaboration agreement with Sarepta Therapeutics (unrated). We believe that this is a positive development for... More
